LY2216684 + Methylphenidate + Placebo (tablet) + Placebo (capsule)

Phase 2/3Completed

0 views this week 0 watching💤 Quiet

Interest: 38/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Attention Deficit Hyperactivity Disorder

Conditions

Attention Deficit Hyperactivity Disorder

Trial Timeline

Jun 1, 2009 → Dec 1, 2010

NCT ID

NCT00922636

About LY2216684 + Methylphenidate + Placebo (tablet) + Placebo (capsule)

LY2216684 + Methylphenidate + Placebo (tablet) + Placebo (capsule) is a phase 2/3 stage product being developed by Eli Lilly for Attention Deficit Hyperactivity Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00922636. Target conditions include Attention Deficit Hyperactivity Disorder.

What happened to similar drugs?

20 of 20 similar drugs in Attention Deficit Hyperactivity Disorder were approved

Approved (20) Terminated (3) Active (0)

✅atomoxetineEli LillyApproved

✅AtomoxetineEli LillyApproved

✅Atomoxetine HydrochlorideEli LillyApproved

✅AtomoxetineEli LillyApproved

✅Atomoxetine hydrochloride + PlaceboEli LillyApproved

✅Atomoxetine + PlaceboEli LillyApproved

✅AtomoxetineEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00922636	Phase 2/3	Completed	Jun 1, 2009	Dec 1, 2010	Attention Deficit Hyperactivity Disorder

Competing Products

20 competing products in Attention Deficit Hyperactivity Disorder

See all competitors

Product	Company	Stage	Hype Score
atomoxetine	Eli Lilly	Approved	39
Atomoxetine + Placebo	Eli Lilly	Phase 2/3	38
Atomoxetine	Eli Lilly	Approved	35
Atomoxetine Hydrochloride	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Phase 3	40
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine hydrochloride + Placebo	Eli Lilly	Approved	43
CLONICEL (Clonidine HCl sustained release)	Shionogi	Phase 3	40
Donepezil hydrochloride + Placebo	Eisai	Phase 3	40
Atomoxetine + Placebo	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Approved	43
Atomoxetine	Eli Lilly	Pre-clinical	26
Atomoxetine Hydrochloride	Eli Lilly	Approved	43
Atomoxetine hydrochloride	Eli Lilly	Phase 3	40
Atomoxetine Hydrochloride + Placebo	Eli Lilly	Approved	43
atomoxetine	Eli Lilly	Phase 3	40
atomoxetine 0.5 mg/kg/day + placebo + atomoxetine 1.2 mg/kg/day + atomoxetine 1.2-1.4 mg/kg/day	Eli Lilly	Phase 3	40
Atomoxetine Hydrochloride	Eli Lilly	Approved	43
Atomoxetine Hydrochloride	Eli Lilly	Phase 3	40
Atomoxetine Hydrochloride + Methylphenidate Hydrochloride + Placebo	Eli Lilly	Phase 3	40